Canada reported on Saturday a second case of rare blood clots with low platelets after immunization with AstraZeneca’s COVID-19 vaccine (AZN.L) in one week, while saying it still recommended the use of the injection.
The person who experienced the very rare event has been treated and is recovering, the Canadian Ministry of Health said in a statement, adding that the person lives in the province of Alberta.
Based on the available evidence, Canada still maintains that the benefits of the AstraZeneca vaccine outweigh the potential risks, according to the statement.
Canadian health authorities “will continue to closely monitor the use of all COVID-19 vaccines and will review and assess any new safety concerns,” the statement said.
Canada reported a first blood clot associated with the vaccine on Tuesday, and a day later, after a review, health authorities said they would not restrict the use of the AstraZeneca vaccine. read more
A separate advisory council had previously recommended that Canada stop offering the vaccine to people under the age of 55. That panel is in the process of reviewing his advice.
Canada has been stepping up its vaccination campaign, but it still has a smaller percentage of its inoculated population than dozens of other countries, including the United States and Great Britain.
Amid a growing third wave of infections, Ontario, Canada’s most populous province, announced new public health restrictions on Friday, including closing the provinces’ borders to domestic travelers. read more
Our Standards: The Thomson Reuters Trust Principles.